Literature DB >> 24913738

Coexistence of Fabry disease and IgA nephropathy: a report of two cases.

G Yin1, Y Wu, C-H Zeng, H-P Chen, Z-H Liu.   

Abstract

BACKGROUND: Coexistence of Fabry disease and IgA nephropathy is rare. Moreover, the coexisting Fabry disease may be unrecognized due to unapparent clinical manifestations.
METHOD: We described two cases with coexisting Fabry disease and IgA nephropathy. The clinicopathological features of these two patients were studied.
RESULTS: A 54-year-old male presented with proteinuria, hematuria, and hypertension, and a 33-year-old male presented with proteinuria without clinical signs or family history of Fabry disease. Both of them were diagnosed with IgA nephropathy at admission, whereas Fabry disease was not suspected. Subsequent immunofluorescent study confirmed the diagnosis of IgA nephropathy by showing positive staining for IgA and complement C3 in the mesangium. Meanwhile, light microscopy showed remarkable vacuolation of podocytes with mild mesangial expansion, which was characteristic of Fabry nephropathy. Further examination of toluidine blue-stained semi-thin sections and electron microscopy demonstrated blue bodies and myelin figures in the cytoplasm of podocytes, respectively. The diagnosis of coexisting Fabry disease was finally established based on deficient α-galactosidase A activity in both patients.
CONCLUSION: This case study is an important reminder of the role of kidney biopsy as an indicator of Fabry disease and its rare coexistence with IgA nephropathy.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24913738     DOI: 10.1007/s11845-014-1161-9

Source DB:  PubMed          Journal:  Ir J Med Sci        ISSN: 0021-1265            Impact factor:   1.568


  17 in total

1.  Fabry disease with few clinical signs and symptoms.

Authors:  Koichi Asahi; Tetsuo Katoh; Kazuo Watanabe; Tsuyoshi Watanabe
Journal:  Intern Med       Date:  2002-11       Impact factor: 1.271

2.  The structure of nephritogenoside. A nephritogenic glycopeptide with alpha-N-glycosidic linkage.

Authors:  S Shibata; T Takeda; Y Natori
Journal:  J Biol Chem       Date:  1988-09-05       Impact factor: 5.157

3.  IgA nephropathy in two adolescent sisters heterozygous for Fabry disease.

Authors:  Catharina Whybra; Andreas Schwarting; Jörg Kriegsmann; Andreas Gal; Eugen Mengel; Christoph Kampmann; Frank Baehner; Ellen Schaefer; Michael Beck
Journal:  Pediatr Nephrol       Date:  2006-07-13       Impact factor: 3.714

4.  Diffuse thin glomerular basement membrane in association with Fabry disease in a Chinese female patient.

Authors:  Zhi-yong Cai; You-kang Zhang; Su-xia Wang; Qiu-yuan Fang; Yu-qing Chen
Journal:  Nephrol Dial Transplant       Date:  2011-08-22       Impact factor: 5.992

5.  Characterization of antibodies against ceramidetrihexoside and globoside.

Authors:  M N Hamers; W E Donker-Koopman; M J Coulon-Morelec; P Dupouey; J M Tager
Journal:  Immunochemistry       Date:  1978-06

6.  [Fabry nephropathy in a female with superposed IgA glomerulonephritis].

Authors:  A Pisani; A Sessa; M Sabbatini; M V Andreucci; C Fusco; M Balletta; B Cianciaruso
Journal:  G Ital Nefrol       Date:  2005 Jul-Aug

7.  Scoring system for renal pathology in Fabry disease: report of the International Study Group of Fabry Nephropathy (ISGFN).

Authors:  Agnes B Fogo; Leif Bostad; Einar Svarstad; William J Cook; Solange Moll; Federic Barbey; Laurette Geldenhuys; Michael West; Dusan Ferluga; Bojan Vujkovac; Alexander J Howie; Aine Burns; Roy Reeve; Stephen Waldek; Laure-Hélène Noël; Jean-Pierre Grünfeld; Carmen Valbuena; João Paulo Oliveira; Justus Müller; Frank Breunig; Xiao Zhang; David G Warnock
Journal:  Nephrol Dial Transplant       Date:  2009-10-15       Impact factor: 5.992

8.  Hemizygous Fabry disease associated with IgA nephropathy: a case report.

Authors:  Homare Shimohata; Keigyou Yoh; Kenji Takada; Hiroaki Tanaka; Joichi Usui; Kouichi Hirayama; Masaki Kobayashi; Kunihiro Yamagata
Journal:  J Nephrol       Date:  2009 Sep-Oct       Impact factor: 3.902

Review 9.  Fabry disease.

Authors:  Dominique P Germain
Journal:  Orphanet J Rare Dis       Date:  2010-11-22       Impact factor: 4.123

10.  The coincidence of IgA nephropathy and Fabry disease.

Authors:  Dita Maixnerová; Vladimír Tesař; Romana Ryšavá; Jana Reiterová; Helena Poupětová; Lenka Dvořáková; Lubor Goláň; Michaela Neprašová; Jana Kidorová; Miroslav Merta; Eva Honsová
Journal:  BMC Nephrol       Date:  2013-01-11       Impact factor: 2.388

View more
  5 in total

Review 1.  Why, when and how should immunosuppressive therapy considered in patients with immunoglobulin A nephropathy?

Authors:  F M Rasche; F Keller; W G Rasche; S Schiekofer; A Boldt; U Sack; J Fahnert
Journal:  Clin Exp Immunol       Date:  2016-09-08       Impact factor: 4.330

2.  Fabry disease and immunoglobulin A nephropathy presenting with Alport syndrome-like findings: A case report.

Authors:  Hang Ren; Lin Li; Jiyun Yu; Shan Wu; Shanshan Zhou; Yang Zheng; Weixia Sun
Journal:  Medicine (Baltimore)       Date:  2019-07       Impact factor: 1.817

3.  IgA nephropathy suspected to be combined with Fabry disease or Alport syndrome: a case report.

Authors:  Wen Hao; Lina Ao; Chenli Zhang; Lei Zhu; Deqiong Xie
Journal:  J Int Med Res       Date:  2019-12-16       Impact factor: 1.671

Review 4.  Multidisciplinary Management of Fabry Disease: Current Perspectives.

Authors:  Luciana Paim-Marques; Rodrigo Joel de Oliveira; Simone Appenzeller
Journal:  J Multidiscip Healthc       Date:  2022-03-10

5.  Frequency of Fabry disease in a juvenile idiopathic arthritis cohort.

Authors:  Luciana Paim-Marques; Amanda Virginia Cavalcante; Islane Verçosa; Paula Carneiro; Marcia Souto-Maior; Erlane Marques; Simone Appenzeller
Journal:  Pediatr Rheumatol Online J       Date:  2021-06-12       Impact factor: 3.054

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.